2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
London C, Gardner H, Mathie T, Stingle N, Portela R, Pennell M, Clifford C, Rosenberg M, Vail D, Williams L, Cronin K, Wilson-Robles H, Borgatti A, Henry C, Bailey D, Locke J, Northrup N, Crawford-Jakubiak M, Gill V, Klein M, Ruslander D, Thamm D, Phillips B, Post G. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLOS ONE 2015, 10: e0124889. PMID: 25923466, PMCID: PMC4414350, DOI: 10.1371/journal.pone.0124889.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, MetronomicAmputation, SurgicalAnimalsBone NeoplasmsCarboplatinCyclophosphamideDiarrheaDisease-Free SurvivalDog DiseasesDogsDrug Therapy, CombinationFemaleIndolesKaplan-Meier EstimateMaleNeutropeniaOsteosarcomaPiroxicamProspective StudiesPyrrolesRegression AnalysisTreatment OutcomeConceptsDisease-free intervalMedian disease-free intervalCarboplatin chemotherapyMetastatic diseaseOverall survivalControl dogsMaintenance therapyAppendicular osteosarcomaMedical conditionsSurvival rateTherapy-associated adverse eventsGross metastatic diseaseMedian overall survivalOutcome of dogsProspective clinical trialsYear survival rateMulti-institutional studyPiroxicam therapyCyclophosphamide therapyAdverse eventsPatient demographicsSupportive careStudy entryMetronomic treatmentClinical trials
2012
Feline exocrine pancreatic carcinoma: a retrospective study of 34 cases
Linderman M, Brodsky E, de Lorimier L, Clifford C, Post G. Feline exocrine pancreatic carcinoma: a retrospective study of 34 cases. Veterinary And Comparative Oncology 2012, 11: 208-218. PMID: 22612638, DOI: 10.1111/j.1476-5829.2012.00320.x.Peer-Reviewed Original ResearchConceptsMedian survivalRetrospective studySurvival timeNon-steroidal anti-inflammatory drug therapyAnti-inflammatory drug therapyOverall median survivalPalpable abdominal massTime of diagnosisMedian survival timeExocrine pancreatic carcinomaHigh metastatic rateMetastatic diseaseAbdominal massClinical presentationMetastatic ratePoor prognosisPrognostic indicatorAggressive tumorsDrug therapyAbdominal effusionPancreatic cancerClinical signsPancreatic carcinomaPatientsWeight loss